My Medical Gateway Blog

My Medical Gateway (MMG) is pleased to announce that HM Hospitales, one of Spain’s leading private healthcare groups, has officially joined the platform. With a network of internationally accredited hospitals renowned for excellence across cardiology, oncology, orthopaedics, diagnostics and women’s health, this partnership enables UK patients to access advanced treatment in Spain at prices significantly below UK private tariffs. World-class care is now available with clarity, speed and full English-speaking coordination.

The addition of HM Hospitales strengthens MMG’s mission to give UK patients access to regulated, accredited care without unnecessary delay, uncertainty or inflated pricing. Founded in 1989, HM Hospitales operates more than 20 hospitals, specialist centres and research institutes across Madrid, Barcelona, Galicia and León, treating over 2.5 million patients annually. Its facilities are recognised for clinical excellence in oncology, cardiac surgery, minimally invasive orthopaedic procedures, reproductive medicine and advanced diagnostics.

For UK patients facing prolonged NHS waiting lists or private quotes exceeding affordability thresholds, the appeal is practical rather than aspirational: the same clinical quality, delivered sooner and at transparent cost. Spain is not a secondary destination for treatment – it is home to some of Europe’s most technologically advanced hospitals, with accreditation standards aligned to ISO, Joint Commission International and EU-wide patient safety regulations.

By joining MMG, HM Hospitales becomes directly accessible to UK self-pay patients through our fully supported “treatment package” pathway: remote consultation, imaging review, treatment planning and post-operative coordination are all managed with English-speaking liaison teams. Travel logistics and local recovery arrangements are built into the service structure, ensuring that treatment abroad does not become an administrative burden.

Why Spain – and Why Now?

Spain has become one of Europe’s most respected healthcare destinations, combining high clinical standards with operational efficiency and patient-centred care. According to OECD benchmarks, Spain consistently ranks above the UK in cancer survival, cardiac mortality reduction and hospital-acquired infection rates. Its medical workforce density exceeds the UK average, and unlike Britain’s current bottlenecks in elective surgery and diagnostics, Spain’s private sector maintains routine access to MRI, CT and surgical intervention without prolonged backlog.

Cost remains one of the strongest differentiators. Hip replacements, cardiac stent procedures or laparoscopic bariatric surgery typically cost 30–50% less than equivalent UK private hospital quotes. Fertility treatments, such as IVF with ICSI or egg donation cycles, are carried out under tightly regulated national protocols at a lower price point than in London or Manchester clinics. Dental restoration, an increasingly common driver of outbound treatment, is often completed within days, not months.

Crucially, affordability does not imply compromise. HM Hospitales integrates clinical research with patient care, operating collaborations with international technology providers and pharmaceutical innovators. Its Madrid-based oncology centre participates in global trials for immunotherapy and precision medicine. Orthopaedic units utilise robotic navigation and rapid-recovery pathways that mirror or exceed UK protocols.

Confidence Built on Regulation, Not Assumptions

Trust remains central to cross-border healthcare. HM Hospitales meets EU accreditation standards and operates under Spain’s Ley de Autonomía del Paciente, which enforces informed consent, data protection and clinical accountability. UK patients visiting Spain retain full rights to pursue legal remedy in the event of malpractice – a critical distinction from unregulated medical tourism sectors elsewhere. MMG is therefore extending its offer not only in quantity of choice, but in depth of assurance.

With HM Hospitales joining the platform, MMG now connects UK patients to one of Southern Europe’s strongest healthcare networks. The agreement expands access not only to core elective procedures but also to advanced diagnostics, women’s health services and chronic care pathways. As outbound treatment becomes a mainstream option rather than a niche exception, infrastructure matters – not just planes and clinics, but coordination, clarity and confidence.

For many patients, the question is no longer whether to consider treatment beyond the UK, but how to do so safely and efficiently. The addition of HM Hospitales makes that decision clearer.